BOLT: Bolt Biotherapeutics Inc. Price to Sales
The volatility of the price-to-sales multiple underscores the high scientific reputation of Bolt Biotherapeutics (BOLT) in developing anticancer conjugates, where the parameter mark equals 2.40. Non-economic demands for oncology innovations ensure the asset's stability by neutralizing market shocks. Business resilience is bolstered by a dedicated staff of immunologists and the recruitment of compliance experts, which smooths the price fluctuations on the chart.
Bolt Biotherapeutics (BOLT) - metric breakdowns and financial figures
- stock price and consensus target price:
- market capitalization information:
- shareholders' equity book value data:
- debt obligations and liquidity statistics:
- financial results and valuation multiples details:
BOLT - Company Net Income|Expected Net Profit Bolt Biotherapeutics|BOLT - Price to Earnings Ratio|Market Cap to Future Earnings Ratio boltbio.com|BOLT - PEG Multiple|Business Value to Operating Income Before Depreciation Bolt Bio|BOLT - Operating profit EBITDA|Net earnings per one share for the last twelve months Bolt Biotherapeutics|BOLT - Earnings per share for the last twelve months|Year-over-year earnings per one share growth for the last 12 months boltbio.com|BOLT - Earnings growth in current year|Earnings growth forecast for next year Bolt Biotherapeutics
- total revenue and sales volume data:
Summary company analytics:Bolt Biotherapeutics Inc., BOLT
The P/S ratio determines the market value of one dollar of revenue, reflecting investor expectations regarding future sales growth rates. Steady confidence in the immunostimulatory antibody platform of Bolt Biotherapeutics (BOLT) supports a high business valuation even with limited current income. Analyzing the history of P/S values allows for a comparison of the asset's current value with its historical averages. This helps identify if the stock is overbought and protects capital from purchasing at local peaks.
Competing companies
argenx.com - Market Cap to Revenue Ratio|P/S Multiple BNTX (BioNTech)|Abivax Pharma (ABVX) - Price to Sales|ADMA Bio - P/S Multiple|PTGX: Price-to-Revenue Ratio|Immunovant, Inc. (IMVT) - Price-to-Revenue Ratio|Price to Sales kiniksa.com (KNSA)|Price-to-Revenue Ratio Grifols|Price-to-Revenue Ratio ADPT|Market Cap to Revenue CLDX (Celldex)|Market Cap to Sales Volume AUPH|BioCryst - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio VERA|Dianthus Therapeutics, Inc. - P/S Multiple|PHVS: Price-to-Revenue Ratio|ABCL: P/S Multiple|TRML - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Precigen, Inc.|Price to Sales pharming.com PHAR|Market Cap to Revenue NKTR (Nektar Therapeutics Inc.)|Market Cap to Sales Volume UPB|P/S Multiple ZBIO (Zenas Biopharma, Inc.)|Market Capitalization-to-Revenue Ratio IMNM|Gossamer Bio, Inc. - P/S Multiple|Price to Sales kalvista.com|Septerna (SEPN) - Price-to-Revenue Ratio|Pieris Pharma - Market Capitalization-to-Revenue Ratio|SVRA (Savara Corp) - P/S Multiple|P/S Multiple Rigel Corp|Price-to-Revenue Ratio AnaptysBio, Inc. (ANAB)|ATXS: Price-to-Sales Ratio|P/S Multiple ENGN (enGene)|RAPT Therapeutics Inc. (RAPT) - Price to Sales|JBIO: Market Cap to Revenue|ACRS - P/S Multiple|KYTX (Kyverna Therapeutics) - Market Cap to Revenue|TLSA: Market Cap to Sales Volume|CABA (Cabaletta Bio) - P/S Multiple|Ventyx Biosciences Inc. (VTYX) - Price-to-Revenue Coefficient|P/S Multiple THTX|Market Cap to Revenue Avalo Therapeutics Inc AVTX|Price-to-Revenue Ratio Eledon Pharmaceuticals ELDN|Price-to-Revenue Coefficient agenusbio.com (AGEN)|Climb Bio - P/S Multiple|ZURA: Price-to-Revenue Ratio|aTyr (ATYR) - Price-to-Revenue Ratio|Price to Sales Adagene Inc. (ADAG)|Price-to-Revenue Ratio ImageneBio|Price-to-Revenue Ratio STTK|Market Cap to Revenue EQ (Equillium, Inc.)|Market Cap to Sales Volume CNTB|Price-to-Revenue Ratio Immunic IMUX|ATRA (Atara Biotherapeutics, Inc.) - Price-to-Sales Ratio|InflaRx GmbH - P/S Multiple|Market Capitalization-to-Revenue Ratio XFOR (x4pharma.com)|ACET: P/S Multiple|Celularity (CELU) - P/S Multiple|Price-to-Revenue Ratio INmune Bio Corp|BRNS: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Kezar Life Sciences (KZR)|Market Cap to Revenue sabbiotherapeutics.com SABS|P/S Multiple AKTX (Akari Therapeutics Plc)|P/S Multiple Enlivex Therapeutics Ltd ENLV|QTTB: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio GOVX (GeoVax Corp)|EDSA: P/S Multiple|IBIO - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Carisma Therapeutics Inc|Market Cap to Revenue XTL Biopharmaceuticals Ltd (XTLB)|Price-to-Revenue Ratio HCW Biologics Inc. (HCWB)|Market Cap to Revenue aptevotherapeutics.com APVO|AIM ImmunoTech Inc. - Market Cap to Revenue|P/S Multiple Aditxt Inc. ADTX|GRI - Price-to-Revenue Ratio|XRTX (XORTX Therapeutics Inc) - Market Cap to Revenue Ratio|HIND: P/S Multiple|Price to Sales Revelation Biosciences Corp (REVB)|INDP (Indaptus Therapeutics) - P/S Multiple|Price-to-Revenue Ratio SCNI|Price-to-Revenue Ratio CalciMedica, Inc. (CALI)|AFMD - Price to Sales|Price-to-Revenue Ratio Allakos ALLK|HOOKIPA Pharma, Inc. - Price-to-Revenue Ratio|IGMS: Market Cap to Revenue|iteostherapeutics.com - Market Cap to Sales Volume|OCEA (Ocean Biomedical) - Market Cap to Revenue|TC BioPharm (Holdings) Plc - Market Capitalization-to-Revenue Ratio|THRD (Third Harmonic Bio, Inc) - P/S Multiple
